Revisiting the role of COX-2 inhibitor for non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Preclinical and clinical studies suggested cyclooxygenase-2 (COX-2) inhibitors may be effective for non-small cell lung cancer (NSCLC).
• Previous phase III trials combining COX-2 inhibitors with chemotherapy did not show survival benefits in unselected advanced NSCLC patients.

Purpose of the Study:

• To evaluate the efficacy of a COX-2 inhibitor combined with chemotherapy in advanced NSCLC, using urinary prostaglandin E metabolite (PGE-M) levels as a predictive biomarker.
• To explore the association between biomarker status and clinical outcomes in NSCLC patients treated with COX-2 inhibitors.

Main Methods:

• A prospective randomized trial was conducted involving advanced NSCLC patients treated with chemotherapy (docetaxel or pemetrexed) plus either a COX-2 inhibitor or placebo.
• Eligible patients had decreased urinary PGE-M levels after a COX-2 inhibitor run-in period, serving as a potential predictive marker.
• Progression-free survival (PFS) was the primary endpoint.

Main Results:

• No significant improvement in PFS was observed in the group receiving the COX-2 inhibitor compared to the placebo group.
• The biomarker strategy, using urinary PGE-M levels, did not translate into improved clinical outcomes for advanced NSCLC patients.

Conclusions:

• Current evidence suggests that COX-2 inhibitors, even when guided by a biomarker like PGE-M, do not offer a survival benefit for advanced NSCLC.
• The clinical utility of COX-2 inhibitors in NSCLC remains questionable, necessitating further investigation into their "difficult" character and potential future strategies.